Rt-PA for ischaemic stroke: What will the next question be?

The Lancet

Volumn 379, Issue 9834, 2012, Pages 2320-2321

  Leys, Didier ^a   Cordonnier, Charlotte ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

AGE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COGNITION; DEMENTIA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EMERGENCY CARE; HUMAN; MORTALITY; NOTE; PRIORITY JOURNAL; SCORING SYSTEM; SURVIVAL; TREATMENT OUTCOME; VASCULAR AMYLOIDOSIS;

EID: 84862588817     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60822-8     Document Type: Note

References (17)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333: 1581-88.
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4·5 hours after acute ischemic stroke. N Engl J Med 2008; 359: 1317-29.
3. Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010; 375: 1695-703.
4. Meretoja A, Putaala J, Tatlisumak T, et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41: 1450-58.
5. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; published online May 23. DOI:10.1016/S0140- 6736(12)60768-5.
6. Wardlaw J, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012; published online May 23. DOI:10.1016/S0140-6736(12) 60738-7.
7. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010; 41: 2840-48.
8. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol 2009; 8: 1006-18.
9. Leys D, Henon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. Lancet Neurol 2005; 4: 752-59.
10. Alshekhlee A, Li C, Chuang S, et al. Does dementia increase risk of thrombolysis? A case-control study. Neurology 2011; 76: 1575-80.
11. Busl KM, Nogueira RG, Yoo AJ, Hirsch JA, Schwamm LH, Rost NS. Prestroke dementia is associated with poor outcomes after reperfusion therapy among elderly stroke patients. J Stroke Cerebrovasc Dis 2011; published online Dec 17. DOI:10.1016/j.jstrokecerebrovasdis.2011.11.005.
12. Cordonnier C, van der Flier WM, Sluimer JD, Leys D, Barkhof F, Scheltens P. Prevalence and severity of microbleeds in a memory clinic setting. Neurology 2006; 66: 1356-60.
13. Neumann-Haefelin T, Hoelig S, Berkefeld J, et al. Leukoaraiosis is a risk factor for symptomatic intracerebral hemorrhage after thrombolysis for acute stroke. Stroke 2006; 37: 2463-66.
14. Fiehler J, Albers GW, Boulanger JM, et al. Bleeding Risk Analysis in Stroke Imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke 2007; 38: 2738-44.
15. Roussel BD, Macrez R, Jullienne A, et al. Age and albumin D site-binding protein control tissue plasminogen activator levels: neurotoxic impact. Brain 2009; 132: 2219-30.
16. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Nat Rev Neurosci 2004; 5: 347-60.
17. Teter B, Ashford JW. Neuroplasticity in Alzheimer's disease. J Neurosci Res 2002; 70: 402-37